Geron's blood cancer drug succeeds in late-stage study, shares surge
/cloudfront-us-east-2.images.arcpublishing.com/reuters/RZHXWJITBVITHB4POUSAWWOPMY.jpg)
Geron Corp said on Wednesday its experimental blood cancer drug helped more patients achieve independence from blood transfusions when compared with a placebo in a late-stage trial, sending its shares up 50%.
Wednesday, January 4, 2023 at 12:26 pm